Moving Forward with Metronomic Chemotherapy: Meeting Report of
the 2nd International Workshop on Metronomic and
Anti-Angiogenic Chemotherapy in Paediatric Oncology

J 2011

Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology

PASQUIER, Eddy, Mark W. KIERAN, Jaroslav ŠTĚRBA, Yuval SHAKED, Sylvain BARUCHEL et. al.

Basic information

Original name

Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology

Authors

PASQUIER, Eddy (36 Australia, guarantor), Mark W. KIERAN (840 United States of America), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), Yuval SHAKED (376 Israel), Sylvain BARUCHEL (124 Canada), Odile OBERLIN (250 France), Maria Sanna KIVIVUORI (246 Finland), Andreas PEYRL (40 Austria), Mamouna DIAWARRA (466 Mali), Michaela CASANOVA (380 Italy), Stergios ZACHAROULIS (826 United Kingdom of Great Britain and Northern Ireland), Gilles VASSAL (250 France), Franck BERTHOLD (276 Germany), Arnauld VERSCHUUR (250 France) and Nicolas ANDRE (250 France)

Edition

TRANSLATIONAL ONCOLOGY, 2011, 1936-5233

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.393

RIV identification code

RIV/00216224:14110/11:00055931

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1593/tlo.11124

UT WoS

000294253200001

Keywords in English

ENDOTHELIAL PROGENITOR CELLS; SOLID TUMORS; ORAL ETOPOSIDE; BRAIN-TUMORS; ANTIANGIOGENIC THERAPY; DOSE CYCLOPHOSPHAMIDE; BREAST-CANCER; CHILDREN; RECURRENT; FUTURE

Abstract

V originále

Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought to act by targeting tumor angiogenesis, additional mechanisms have been recently unveiled, and metronomic chemotherapy is now considered to represent a form of multitargeted therapy. Despite representing a genuine alternative for advanced and/or high-risk cancer therapy, the development of metronomic approaches in pediatric oncology still in the early stage. The few numbers of large-scale state-of-the-art clinical trials, issues regarding terminology and the limited understanding of the complex and intertwined mechanisms of action of metronomic treatments have limited progress in this important field of research. On March 18 and 19, 2010, the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology was held in Marseille, France, and brought together clinicians, basic scientists, physician-scientists, trainees, and students from all around the world. The main aim of this international meeting was to provide a unique forum to 1) reflect on the major advances that have been made in this field of research since its creation, 2) communicate results from the most recent clinical trials and preclinical studies, 3) discuss the current and future challenges of the field, and 4) set forth a solid framework for future collaborative biologic and clinical studies. The present report documents the main preclinical and clinical data that were presented in the keynote and best abstract sessions and delivers the key messages from the meeting.

Citovat

PASQUIER, Eddy, Mark W. KIERAN, Jaroslav ŠTĚRBA, Yuval SHAKED, Sylvain BARUCHEL, Odile OBERLIN, Maria Sanna KIVIVUORI, Andreas PEYRL, Mamouna DIAWARRA, Michaela CASANOVA, Stergios ZACHAROULIS, Gilles VASSAL, Franck BERTHOLD, Arnauld VERSCHUUR and Nicolas ANDRE. Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. TRANSLATIONAL ONCOLOGY. 2011, vol. 4, No 4, p. 189-197. ISSN 1936-5233. Available from: https://dx.doi.org/10.1593/tlo.11124.

@article{974264,
   author = {Pasquier, Eddy and Kieran, Mark W. and Štěrba, Jaroslav and Shaked, Yuval and Baruchel, Sylvain and Oberlin, Odile and Kivivuori, Maria Sanna and Peyrl, Andreas and Diawarra, Mamouna and Casanova, Michaela and Zacharoulis, Stergios and Vassal, Gilles and Berthold, Franck and Verschuur, Arnauld and Andre, Nicolas},
   article_number = {4},
   doi = {http://dx.doi.org/10.1593/tlo.11124},
   keywords = {ENDOTHELIAL PROGENITOR CELLS; SOLID TUMORS; ORAL ETOPOSIDE; BRAIN-TUMORS; ANTIANGIOGENIC THERAPY; DOSE CYCLOPHOSPHAMIDE; BREAST-CANCER; CHILDREN; RECURRENT; FUTURE},
   language = {eng},
   issn = {1936-5233},
   journal = {TRANSLATIONAL ONCOLOGY},
   title = {Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology},
   volume = {4},
   year = {2011}
}

TY  - JOUR
ID  - 974264
AU  - Pasquier, Eddy - Kieran, Mark W. - Štěrba, Jaroslav - Shaked, Yuval - Baruchel, Sylvain - Oberlin, Odile - Kivivuori, Maria Sanna - Peyrl, Andreas - Diawarra, Mamouna - Casanova, Michaela - Zacharoulis, Stergios - Vassal, Gilles - Berthold, Franck - Verschuur, Arnauld - Andre, Nicolas
PY  - 2011
TI  - Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology
JF  - TRANSLATIONAL ONCOLOGY
VL  - 4
IS  - 4
SP  - 189-197
EP  - 189-197
SN  - 19365233
KW  - ENDOTHELIAL PROGENITOR CELLS
KW  - SOLID TUMORS
KW  - ORAL ETOPOSIDE
KW  - BRAIN-TUMORS
KW  - ANTIANGIOGENIC THERAPY
KW  - DOSE CYCLOPHOSPHAMIDE
KW  - BREAST-CANCER
KW  - CHILDREN
KW  - RECURRENT
KW  - FUTURE
N2  - Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought to act by targeting tumor angiogenesis, additional mechanisms have been recently unveiled, and metronomic chemotherapy is now considered to represent a form of multitargeted therapy. Despite representing a genuine alternative for advanced and/or high-risk cancer therapy, the development of metronomic approaches in pediatric oncology still in the early stage. The few numbers of large-scale state-of-the-art clinical trials, issues regarding terminology and the limited understanding of the complex and intertwined mechanisms of action of metronomic treatments have limited progress in this important field of research. On March 18 and 19, 2010, the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology was held in Marseille, France, and brought together clinicians, basic scientists, physician-scientists, trainees, and students from all around the world. The main aim of this international meeting was to provide a unique forum to 1) reflect on the major advances that have been made in this field of research since its creation, 2) communicate results from the most recent clinical trials and preclinical studies, 3) discuss the current and future challenges of the field, and 4) set forth a solid framework for future collaborative biologic and clinical studies. The present report documents the main preclinical and clinical data that were presented in the keynote and best abstract sessions and delivers the key messages from the meeting.
ER  -

PASQUIER, Eddy, Mark W. KIERAN, Jaroslav ŠTĚRBA, Yuval SHAKED, Sylvain BARUCHEL, Odile OBERLIN, Maria Sanna KIVIVUORI, Andreas PEYRL, Mamouna DIAWARRA, Michaela CASANOVA, Stergios ZACHAROULIS, Gilles VASSAL, Franck BERTHOLD, Arnauld VERSCHUUR and Nicolas ANDRE. Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. \textit{TRANSLATIONAL ONCOLOGY}. 2011, vol.~4, No~4, p.~189-197. ISSN~1936-5233. Available from: https://dx.doi.org/10.1593/tlo.11124.

Detailed Information on Publication Record